.png){kind=icon}
.png){kind=icon}
Return
Safety and immunogenicity of a reduced, homologous booster dose of the BNT162b2 mRNA COVID-19 vaccine: a single blind, randomized, non-inferiority follow-up trial
.png){kind=icon}
OA
AI
S
P
S
A
L
D
M
A
I
M
DOI：10.1016/j.vaccine.2026.128897.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Reduced booster (3rd) dose of BNT162b2 (10 μg) safe and with less reactogenicity. • At day 28, reduced-dose elicited slightly inferior humoral immune response. • At month 6, no more significant difference in the humoral immune response. • Similar post-booster breakthrough infections frequency/symptomatology in both arms. • Multiple benefits of dose-sparing strategy.
Keywords:
SARS-CoV-2
Fractional doses
Vaccines
Antibodies
Humoral immune response
Adverse events
Breakthrough infections
Booster dose
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
3.5
Papers:
2.1K
Citations:
4.7W
Organization
Cited Papers